As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.

Ranbaxy loses Valcyte exclusivity: An analysis

Ranbaxy has first-to-file status, meaning eligibility for six months of generic sales exclusivity for both AstraZeneca's heartburn drug Nexium & Roche's antiviral drug Valcyte drugs. However, the final approvals for these drugs were delayed because of the compliance issues at Ranbaxy's plants.

DRL-GSK generic formulations deal under review: PharmAsia

The DRL-GSK deal was to sell branded generic formulations in emerging markets and was entered into in 2009.

R&D spend to go up by 9-10% in next few years: Dr Reddy‘s

Dr Reddy's Labs has signed an agreement with Galena Biopharma to develop NeuVax in India.

JB Chem to use major sale proceeds to reward shareholders

Leading global pharmaceutical company JB Chemical has sold its prescription business to Dr Reddy's for USD 35 million. In an exclusive interview with CNBC-TV18, the company’s president, Pranabh Mody says a significant part of the cash earned from the sell will be used to reward shareholders.

What is Lupin's acquisition agenda for the future?

Kamal Sharma, Managing Director of Lupin, started four decades ago almost as a stockiest and C&F agent. Today, his company is one of India’s largest drug manufacturers and the 5th largest generic drug manufacturer in the world.

Ranbaxy, Merck call off anti-infectives deal

Drug majors Ranbaxy and Merck have called off a deal that would have seen both the pharma giants join hands to research anti-infectives, reports PharmAsia News. The deal between the two companies was struck in 2008. Ranbaxy was to get milestones and an undisclosed upfront fee as part of the deal.